BIOGRAPHICAL SKETCH

Academic & Professional Background

• M.D. 1982 - University Central del Caribe, Cayey, Puerto Rico
• Residency (Internal Medicine) 1986 - Providence Hospital, Washington, DC

Current Research Interests

• Pulmonary Disease
• COPD
• Clinical Trials

Selected Publications

Ayoub IM, Kolarova JD, Yi Z, Maldonado FM, Gazmuri RJ. NHE-1 inhibition prevents episodes of recurrent VF after resuscitation from cardiac arrest. Circulation (in press), 2003.

Gazmuri RJ, Maldonado FA. Post-resuscitation management. In: CPR: Resuscitation of the Arrested Heart. Weil MH, Tang W (Eds), WB Saunders, Philadelphia, pp. 179-191, 1999.

Maldonado FA, Gluck EH, Franklin CM. Acute poisoning I: General management. Hospital Physician 1997 2(3)L:1-12, 1997.

Maldonado FA, Gluck EH, Franklin CM, Sorresso DJ, Jolepalem J. Acute poisonings II: Specific agents. Hospital Physician 2(4):1-12, 1997.

Maldonado FA, Weil MH, Tang W, Bisera J, Gazmuri RJ, Johnson B, D'Alessio A. Myocardial hypercarbic acidosis reduces cardial resuscitability. Anesthesiology 78:343-352, 1993.

Projects Completed or Active (Selected)

• A Phase 2 Study to Determine the Efficacy and Safety of Sivelestat in Patients with Acute Lung Injury
• A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial Assessing the Proportion of Patients Experiencing an Exacerbation and Proportion of Patients Hospitalized for an Exacerbation Over 6 Months During Treatment with Tiotropium 18 mcg Capsule Once Daily in Patients with COPD in a Veterans Affairs Setting
• A Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Investigate the Long-Term Effects of Salmeterol/Fluticasone Propionate (Seretide™/Viani™/Advair™) 50/500µg bd, Salmeterol 50µg bd and Fluticasone Propionate 500µg bd, All Delivered Via the Diskus/™Accuhaler™ Inhaler, on the Survival of Subjects with Chronic Obstructive Pulmonary Disease (COPD) over 3 years of Treatment
• A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Oral Gemifloxacin (Factive TM) 320mg Once Daily for 5 Days versus Oral Levofloxacin 500mg Once Daily for 7 Days for the Treatment of Acute Exacerbations of Chronic Bronchitis
• Linezolid (PNU-100766) in the Treatment of Patients with Nosocomial Pneumonia. A Double-Blind, Randomized, Comparator Controlled Study
• Antithrombin III in Patients with Severe Sepsis. A Multinational, Double-Blind, Randomized, Placebo-Controlled Phase-III Study

Research Funding Sources

• Boehringer Ingelheim
• Centeon Pharma GmbH
• Eli Lilly and Company
• Glaxo Smith Kline
• Pharmacia & Upjohn
• SmithKline Beecham

Professional Accomplishments

• Member, Chicago Critical Care Society
• Member, Society of Critical Care Medicine
• Member, American College of Chest Physicians
• Member, National Association of Inpatient Physicians

Honors and Awards

• 1998 - Fellow, American College of Chest Physicians
• 1997 - Vice Presidential Hammer Award for Reinventing Government: Compensation and Pension Joint Claims Team, North Chicago VA Medical Center
• 1994 - Vice Presidential hammer Award for Reinventing Government: Primary Care program Steering Team, North Chicago VA Medical Center
• 1993 - The Max Harry Weil, MD Clinical Educator Award, Department of Medicine, Finch University of Health Sciences, The Chicago Medical School
• 1991 - DuPont Pharmaceuticals/ACCP Young Investigator Award, American College of Chest Physicians
• 1991 - Henry Christian Award for Excellence in Research, American Federation for Clinical Research